GSK Triumphs in Zantac Litigation Case

GlaxoSmithKline (GB:GSK) has released an update.

GlaxoSmithKline (GSK) has announced a legal victory as the plaintiff voluntarily dismissed the upcoming Zantac case in Illinois without any settlement or payment from GSK. The company reaffirms its position, citing 16 epidemiological studies that found no credible link between ranitidine, the drug in question, and cancer risk. GSK pledges to continue defending its interests and managing litigation proactively for the benefit of the company and its shareholders.

For further insights into GB:GSK stock, check out TipRanks’ Stock Analysis page.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.